New results have been published from one of the first placebo-controlled clinical trials investigating the effects of microdosing Lysergic Acid Diethylamide (LSD). This Phase 1 trial is the first step in testing whether these kinds of psychedelic microdose methods could be useful as a therapeutic approach for treating Alzheimer’s disease, and while the early data doesn’t identify significant cognitive benefits in microdosing, it certainly demonstrates the method is safe enough to proceed to larger efficacy trials.
Read full article on NewAtlas.
Thanks very interesting blog!
Excellent post. I was checking constantly this blog and I’m inspired!
Very helpful information specifically the last part 🙂 I take care
of such info a lot. I was looking for this certain info for
a very long time. Thank you and good luck. https://www.homify.in/ideabooks/8280070